1E Therapeutics Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
1E Therapeutics Ltd. - overview
Established
2020
Location
-, -, Israel
Primary Industry
Biotechnology
About
Founded in 2020 and based in Israel, 1E Therapeutics Ltd. is a drug development company creating RNA-targeting therapeutics based on a proprietary drug design platform. Dr. Ido Bechelt is the founder of the company.
In December 2021, 1E Therapeutics Ltd. raised USD 120 million in Seed funding from individual and unspecified investors. The company provides RNA(ribonucleic acid)-targeting drugs to help treat a wide array of indications in oncology, age-related diseases, immunology, viral infections, anti-microbial resistance, and orphan neurological disorders. This enables the creation of individualized therapeutics to specifically target each stage of a patient's disease.
The organization plans to use the December 2021 funding for its development plans and to hire its CMC, research, development, manufacturing teams.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.1etx.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.